Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience
Hematological Oncology · 2024
DOI: 10.1002/hon.3273 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Hematological Oncology, 2024. Verfasst von Vittorio Ruggero Zilioli und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy. Hauptthemen laut MEDLINE: Hodgkin Disease, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Few data are known regarding the use of interim positron emission tomography (iPET) after the first two cycles (iPET2) of chemotherapy in treatment‐naïve classical Hodgkin lymphoma (cHL) in routine clinical practice, and about the real‐life adoption of intensification strategies for iPET positive patients. We conducted a multicenter retrospective study on cHL to investigate the use of iPET in the real‐life setting, its prognostic role and outcomes of patients early shifted to intensification. Six hundreds and forty‐one patients were enrolled (62% had advanced stage). iPET2 was positive in 89 patients (14%) including 8.7% and 17% early and advanced stage patients, respectively ( p = 0.003). Among iPET 2 positive cases treatment was immediately modified in 19 cases; in 14 cases treatment was modified after an additional positive iPET4. Overall 56 iPET2 positive patients never received intensified therapies. Most frequently used intensified therapy was autologous stem cell transplantation followed by BEACOPP. After a median follow‐up of 72 months, the 5‐year progression‐free survival (PFS) was 82% with iPET2 positive patients showing a worse PFS compared with iPET2 negative cases: 31% versus 85%. Focusing on advanced stage patients with a positive iPET2, the 5‐year PFS was 59% for patients shifted to intensified therapy at any time point versus 61% for patients who never received intensified therapy. Our study confirmed the higher curability of naïve cHL patients in a real‐world setting, and the prognostic role of iPET2 in this setting. A poor adherence to response‐adapted strategy which however did not translate into a difference in patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
- Hematology, Azienda Ospedaliera Universitaria Senese & University of Siena, Siena, Italy.
- U.O.C. Ematologia e T.M.O., AORN "S.G. Moscati", Avellino, Italy.
- U.O.C. di Ematologia con Trapianto di Midollo Osseo, A.U.O. "San Giovanni di Dio e Ruggi D'Aragona", Salerno, Italy.
- Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
- Hematology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy.
ORCID-Profile: Vittorio Ruggero Zilioli, Emanuele Cencini
Zitieren
APA
Zilioli, V. R., Cencini, E., Lorenzo, S., Pezzullo, L., Merli, M., Rivellini, F., Muzi, C., Emiliano, B., Marcheselli, L., & Luminari, S. (2024). Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience. Hematological Oncology. https://doi.org/10.1002/hon.3273
Vancouver
Zilioli VR, Cencini E, Lorenzo S, Pezzullo L, Merli M, Rivellini F, et al. Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience. Hematological Oncology. 2024. doi:10.1002/hon.3273
BibTeX
@article{Zilioli2024,
author = {Zilioli, Vittorio Ruggero and Cencini, Emanuele and Lorenzo, Sonya De and Pezzullo, Luca and Merli, Michele and Rivellini, Flavia and Muzi, Cristina and Emiliano, Barbieri and Marcheselli, Luigi and Luminari, Stefano},
title = {Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience},
journal = {Hematological Oncology},
year = {2024},
doi = {10.1002/hon.3273}
}
EUVIMED